News

Tian Zhang, MD, discusses the challenges associated with vaccine development in kidney cancer and the hope that vaccines can still be the answer to improving the response rates with anti¬–PD-1/PD-L1 treatment in RCC.

Carolyn E. Banister, MD, highlights the major findings of her study that discovered a new subtype of cervical cancer and the significant therapeutic implications that will follow. 

Two separate delays have been announced by Bristol-Myers Squibb and AstraZeneca in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib for patients with <em>BRAF</em>-mutant unresectable melanoma.

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab have demonstrated that the combination was well-tolerated with no dose-limiting toxicities in early-stage melanoma.

Cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors, according to the results of a single-arm phase II study.&nbsp;

In an analysis of 2 randomized trials,patients with advanced gastric or gastroesophageal juncture cancer derived a survival benefit from treatment with the monoclonal antibody ramucirumab, regardless of their age.<br /> &nbsp;

Supporting the concept of post-progression survival and the influence of different patterns of progression, a new analysis showed patients with advanced HCC had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression.

Continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

Roy Herbst, MD, PhD, discusses the next steps with pembrolizumab in non-small cell lung cancer following its FDA approval, including combination regimens. &nbsp;

Chi Van Dang, MD, PhD, has been appointed scientific director of the Ludwig Institute for Cancer Research.

Genetic counselor Krista Qualmann, MS, CGC,&nbsp;discusses the syndromes she is identifying in patients in her clinic, as well as how they could impact brain tumor treatment.

The use of tumor treating fields as a treatment for patients with brain tumors has, thus far, largely been focused on in glioblastoma, but an upcoming trial aims to expand the use of the device to the grade III patient population, says Daniel O&rsquo;Connell, MD.

Martin J. Edelman, MD, has joined Fox Chase Cancer Center as chair of the Department of Hematology/Oncology and deputy cancer center director for clinical research.

Neoadjuvant chemotherapy with nanoparticle albumin-bound nab-paclitaxel has demonstrated substantial activity across major subgroups of breast cancer, a meta-analysis of clinical trials showed.

Denise A. Yardley, MD, discusses the tnAcity clinical trial results and current role of nab-paclitaxel in TNBC, as well as the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

The combination of the Fc-modified monoclonal antibody margetuximab with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients.

Sarcoma physician and researcher Robert G. Maki, MD, PhD, has joined the leadership team at Northwell Health Cancer Institute.

Arie Perry, MD, chief of neuropathology at UCSF in San Francisco, California, discusses what oncologists should be aware of when diagnosing patients after these reclassifications, how it could change pathology, as well as a discussion on hereditary tumors.

Elizabeth Loggers, MD, PhD, discusses the findings of the phase II SARC028 trial in sarcoma.

The results of a recent randomized study showed anti-HER2 DC1 vaccination to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.

While mutations of the <em>BRCA</em> gene can increase a woman&rsquo;s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Claire Verschraegen, MD, discusses the design and findings of an early trial of avelumab and the future potential for the PD-L1 inhibitor in lung cancer.

Maria Ignez Braghiroli, MD, discusses a study that parsed out patients with solely NRAS-mutated colorectal cancer, what the current treatment paradigm is for these patients, and how the mutation status of a patient with colorectal cancer may affect their treatment.

Chung-Han (Joe) Lee, MD, discusses&nbsp;recent treatment approvals in RCC, current and emerging treatments and strategies, and the significance of clinical trial enrollment.

Michael J. Morris, MD, discusses&nbsp;the use of bone-seeking radiopharmaceuticals in prostate cancer, with a specific focus on radium-223.

A supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin has been granted priority review by the FDA as a treatment for patients with metastatic or advanced non-squamous non&ndash;small cell lung cancer without <em>EGFR</em> or <em>ALK</em> mutations and regardless of PD-L1 expression.